Research Funding

The Pediatric Early Phase-Clinical Trials Network (PEP-CTN) grant, supporting 21 premier Children’s Oncology Group (COG) pediatric core member sites in the U.S. and 21 non-core member sites in the U.S., Canada and Australia charged with early phase clinical trials, is primarily funded by the National Cancer Institute (NCI) and also receives additional funding from other granting agencies and from philanthropic sources (http://thecogfoundation.org).

Primary funding for the PEP-CTN  is through an NCI UM1 grant mechanism.  Reviewer comments from  the 2024 grant renewal included:

• “PEP-CTN plays a strategically critical role in the mission of improving the care of children and adolescents with cancer. Its unique place and capabilities within the global environment of pediatric oncology clinical research cannot be overstated.”
  
• “The COG PEP-CTN has capabilities to identify, prioritize, operationalize and manage trials via CTEP-held, company-held or COG-held INDs.”
  
• "The PEP-CTN has a powerful organizational structure with a strong track record of productivity as demonstrated by the steady implementation and completion of early phase studies."